OBJECTIVE：To provide reference for improving the clopidogrel rational use in cerebral infarction secondary prevention. METHODS： Medical cases of 471 patients with acute cerebral infarction in neurology department in a hospital from 2013 to 2014 were retrospective surveyed to collect the utilization rate of clopidogrel and the combination of clopidogrel with proton pump inhibitors （PPIs） and aspirin， and the rationality was analyzed. RESULTS： The utilization rate of clopidogrel in cerebral infarction secondary prevention was 93.84％； the combination rate with PPIs was 52.49％， of which， 51.72％ had no drug selection or combined treatment basis； the combination rate with aspirin was 40.72％， cardiogenic cerebral infarction accounted for only 3.9％， non-cardiogenic cerebral infarction accounted for 96.1％， and recurrence of cerebral infarction in high-risk patients accounted for 31.11％. CONCLUSIONS：Clopidogrel in patients with cerebral infarction secondary prevention is widely used in the hospital， has high combination rate with PPIs and aspirin and low guide compliance rate. Clopidogrel should be enhanced pharmacy services， comply with evidence based medicine and improve the rationality of medication.